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Background: Despite the increased rate of complete response to initial chemotherapy, most patients with
advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy
has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The
present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC).
Methods: This retrospective study included 56 ROC patients who initially received standard chemotherapy followed
by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August
2013. The adverse events (AEs) and clinical responses were examined.
Results: No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed
an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the
first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L
before vaccination were identified as significant independent factors by multivariate Cox proportional hazard
analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and
11.6 months, respectively. The corresponding disease control rates were 36% and 15%, respectively.
Conclusions: Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy
for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.
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According to a 2012 estimate, approximately 22,280 new
cases of ovarian cancer (OC) are diagnosed and 15,500
women die of the disease in the United States annually
[1]. OC is often detected when the disease is already
widespread in the abdomen, with approximately 40–50%
of all patients being diagnosed with stage III or IV dis-
ease [2]. The standard approach to OC treatment is
debulking surgery, followed by combined platinum and* Correspondence: m2nagaya@marianna-u.ac.jp
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unless otherwise stated.taxane chemotherapy [3,4]. Although significant pro-
gress in OC treatment has been achieved, approximately
55% of all patients develop recurrence within 2 years,
and more than 70% of patients show recurrence within
5 years [2]. Patients with recurrent disease often receive
additional second- and third-line chemotherapy regimens.
In cases of resistance to platinum-based therapy, second-
line single-agent chemotherapy with non-platinum drugs is
offered, with a short-lived response rate of approximately
10–25%, regardless of drug types. Combination therapies
have been suggested to offer no clinical benefits in these
patients [5]. Most patients therefore receive only palliative
care, indicating an urgent need for alternative approaches
that could improve the survival rates of patients with re-
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cells that are characterized by their efficient presentation
of internalized antigens with major histocompatibility
complexes (MHCs), required to orchestrate T-cell re-
sponses [6]. The first DC vaccination study was reported in
1996 [7], and a few clinical trials of DC-based immuno-
therapy for OC have been conducted [8-10]. However,
these trials included patients with all stages of OC and had
small sample sizes, thus making it difficult to accurately as-
sess the efficacy of DC immunotherapy in ROC.
In 2009, the cancer antigen prioritization project of
the National Cancer Institute ranked Wilms tumor 1
(WT1) as the first antigen, followed by mucin 1, cell-
surface associated (MUC1) [11]. The oncogenic WT1 is
expressed in various types of hematological and solid
malignancies, including OC. The expression frequency
of WT1 in OC ranges from 62% to 78% in immunohis-
tochemistry (IHC) studies [12,13].
MUC1 is a heavily glycosylated membrane glycopro-
tein with 5 potential O-glycosylation sites in each of its
20 amino acid-long tandem repeats, which comprise
most of the extracellular domain [14]. Numerous studies
have shown that MUC1 is widely expressed on carcin-
omas, including those of the breast, colon, rectum,
stomach, and lung, as well as OC [15]. Wang et al. [16]
reported that MUC1 expression was detected by IHC in
90% of OC cases. Additionally, cancer antigen (CA)-125
has also been detected in tissue sections of human epi-
thelial OC, but not in normal ovarian tissue. Høgdall
et al. [17] confirmed that CA125 expression was ob-
served in 70% of all examined OC tissue samples.
Although WT1, MUC1, and CA125 are considered
tumor antigens and potential targets for cancer immuno-
therapy, no reports are available on these antigens in ROC.
Therefore, we retrospectively investigated the safety, im-
munological responses, and clinical effects of DC vaccines
targeting synthesized peptides in ROC patients.
Materials and methods
Patient selection
This retrospective study included patients who initially
received chemotherapy for ROC followed by DC-based
immunotherapy targeting synthesized peptides at the Seren
Clinics in Nagoya and Tokyo between March 2007 and
August 2013. The inclusion criteria were as follows: (1) a
clinical diagnosis of inoperable ROC; (2) an expected prog-
nosis of more than 3 months; (3) white blood cell count of
2,000 cells/μL or higher; (4) hemoglobin level of 7.0 g/dL
or higher; (5) platelet count of 70,000 counts/μL or higher,
and (6) no serious vital organ dysfunction. All participants
provided signed informed consent for use of their data for
this study. This study was approved by the institutional re-
view board of Isoukai (approval number 25–2) and was
conducted in accordance with the Declaration of Helsinki.DC preparation
To determine the type of peptides for administration, we
first evaluated each patient for human leukocyte antigen
(HLA) expression. In cases of available patient tissue
samples, WT1 and/or MUC1 expression was assessed via
IHC staining. Serum CA125 levels were also evaluated
to determine the peptide to be administered. Based on
these results, DCs were prepared and pulsed with 1–3
synthesized peptides as previously described [18,19].
Briefly, peripheral blood mononuclear cells (PBMCs)
were prepared from leukapheresis products by Ficoll-
Hypaque gradient density centrifugation. PBMCs were
then plated on tissue culture vessels and continuously
cultured for 5 days in medium containing granulocyte-
monocyte colony-stimulating factor (GM-CSF; 50 ng/mL)
and interleukin (IL) 4 (25 ng/mL) to generate immature
DCs. To induce further differentiation, the immature
DCs were stimulated with OK-432 (Chugai Pharma-
ceutical Co, Ltd, Tokyo, Japan) and prostaglandin-E2
(50 ng/mL; Daiichi Fine Chemical Co, Ltd, Toyama,
Japan) for 24 hours. On day 7 in culture, the DCs were
pulsed with MHC class I-restricted WT1 peptide antigens
according to the HLA-A pattern (CYTWNQMNL [mutant
WT1 peptide; Neo-MPS, San Diego, CA] for HLA-A*2402
or RMFPNAPYL [WT1 peptide; Neo-MPS] for HLA-
A*0201/0206), MUC1 long peptide (30-mer [TRPAPG-
STAPPAHGVTSAPDTRPAP-GSTAP] at 20 mg/mL;
Greiner Japan, Tokyo, Japan) for any HLA-A type, and/or
CA125 protein (500 U/mL) for any HLA-A type. Subse-
quently, the DCs were characterized by flow cytome-
try to ensure that they achieved the typical phenotype
of mature DCs (CD14-/low/HLA-DR+/HLA-ABC+/CD80+/
CD83+/CD86+/CD40+/CCR7+). They were then cryopre-
served until the day of administration.
Treatment
The DC suspension was adjusted to a total volume of
1.0 mL using saline. All patients were intradermally
injected 5–7 times with DCs (approximately 107 cells/
injection) in close proximity to the axial and/or inguinal
lymph nodes. Injections were repeated every 14–21 days.
OK-432, a streptococcal immunological adjuvant, was ad-
ministered simultaneously with the DC vaccine to pa-
tients without serious allergies to penicillin or other
drugs. Tolerable doses of OK-432 ranged from 0.5 to 5
KE, and the appropriate doses were determined accord-
ing to the incidence of fever after administration.
Immunological assessment
Immunological function was found to be associated with
survival on DC vaccine administration. For the functional
analysis of cancer immunotherapy, CD4+ T cells, CD8+
T cells, and natural killer (NK) cells were obtained from
blood samples before and after DC vaccine administration.
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flow cytometry were considered to be NK cells.
Tetramer staining
WT1-specific cytotoxic T lymphocytes (CTLs) were also
evaluated for adequate induction. The frequency of
WT1-specific CTLs in each patient was determined with
either WT1-HLA-A*2402 or 0201 tetramers by flow cy-
tometry analysis as previously described [18]. Briefly,
T cells were incubated with Clear Back (MBL, Nagoya,
Japan) prior to tetramer staining to block the Fc receptors.
They were then stained with phycoerythrin-labeled HLA-
A*2402 WT1 mutated (CYTWNQMNL) and HLA-
A*0201 WT1 wild-type (RMFPNAPYL) tetramers (MBL),
followed by fluorescein isothiocyanate-labeled anti-human
CD3, CD4, and CD8. The staining was performed at 4°C
for 30 minutes, and the cells were washed twice before
flow cytometry analysis.
Evaluation
All adverse events (AEs) were graded and documented ac-
cording to the Common Terminology Criteria for Adverse
Events, version 4.0. Clinical assessments were performed at
baseline, 3 months, and 6 months via computed tomog-
raphy (CT) or magnetic resonance imaging (MRI). Re-
sponse was expressed as the proportion of patients with a
complete response (CR), partial response (PR), stable dis-
ease (SD), or progressive disease (PD), as well as disease
control rate (DCR) or objective response rate (ORR), as
assessed according to the Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1. We assessed transient
erythema in the patients’ forearm skin within 24–48 h after
vaccination. Fever after vaccination was also assessed and
defined as a body temperature of ≥38°C at 48 hours after
vaccination. In addition, we used the neutrophil-to-
lymphocyte ratio (NLR) as a simple index of systemic in-
flammation [20].
Statistical analyses
The Kaplan-Meier probability estimates of overall survival
(OS) were calculated, and statistical differences between
the treatment arms were determined using the log-rank
test. A multivariate analysis was performed using the Cox
regression method to estimate the hazard ratios (HRs) with
a 95% confidence interval (CI). Categorical data were
compared using the Fisher exact probability test or the
chi-square test. Differences were considered statistically
significant when P values were <0.05.
Results
Patients
A total of 71 patients who initially received chemother-
apy for ROC followed by DC-based immunotherapy were
included in our study. Of these, 8 patients who receivedless than 5 rounds of the DC vaccine and 5 who were un-
available for follow-up examinations were excluded. Two
patients who received the DC vaccine pulsed with pep-
tides eluted from autologous OCs were also excluded.
Thus, the final analysis included 56 eligible patients
whose clinicopathological characteristics are summarized
in Table 1. The patients’ age ranged from 23 to 70 years
(median, 55.0 years). Histological diagnoses included
serous cystadenocarcinoma (n = 37), endometrioid adeno-
carcinoma (n = 6), clear cell adenocarcinoma (n = 5), others
(n = 4, Additional file 1: Table S2), and unknown (n = 4).
Forty-six patients received DCs pulsed with WT1 (WT1
only, n = 7; WT1 +MUC1, n = 31; WT1 +MUC1 +CA125,
n = 3; and WT1 +CA125, n = 5), whereas the others re-
ceived DCs pulsed with MUC1 and/or CA125. All patients
in this study had initially received chemotherapy for ROC.
Of these, 27 (48%) received platinum-based chemo-
therapy while the others (52%) received non-platinum-
based chemotherapy or received no chemotherapy during
DC vaccination.
Toxicity and AEs
The AEs were tolerable in all patients. No serious acute
allergic reaction such as anaphylaxis was observed. The
most common AEs were injection site reaction (68%)
and fever (32%). Other common AEs such as arthralgia
and elevated liver enzyme levels were not observed. No
grade 3–4 toxicity or evidence of autoimmune sequelae
was documented.
Immunological assessment
Fever and erythema after vaccination and frequencies of
CD4+ T cells, CD8+ T cells, and NK cells were examined
to assess immunological function. However, no remark-
able changes were observed in CD4+ T cell, CD8+ T cell,
and NK cell frequencies after vaccination (Figure 1A–C).
In addition, none of these factors affected the median sur-
vival time (MST). Forty-six of the 56 patients received DCs
pulsed with WT1 peptide, 17 of whom were evaluable for
WT1-specific CTLs. The frequency of WT1-specific CTLs
increased in 12 of these examined patients (70.6%; P = 0.04;
Figure 2 and Additional file 1: Table S2). However, no sig-
nificant differences in clinical outcomes were observed be-
tween patients with WT1-specific CTL increase and those
without such an increase.
Clinical outcomes
Clinical responses were evaluated in 56 patients. The
MST from diagnosis was 30.4 months and that from the
first vaccination was 14.5 months (Figure 3, left). The
1- and 2-year survival rates from diagnosis were 87%
and 65%, respectively. Therapeutic efficacy was evaluated
according to RECIST in all 56 patients at 3 months after
the first vaccination, and none of the patients showed CR.
Table 1 Patient characteristics
Overall Albumin ≥ 4.0 Albumin < 4.0 P value
Number of patients 56 36 20
Age (year) 0.6563
Median (range) 55 (23–70) 52 (23–70) 56 (28–68)
ECOG performance status score – no. (%) 0.0877
0 -1 48 (86) 33 15
2- 8 (14) 3 5
Histological diagnosis – no. (%) 0.2583
Serous cystadenocarcinoma 37 (66) 25 12
Endometrioid adenocarcinoma 6 (11) 5 1
Clear cell adenocarcinoma 5 (8.9) 2 3
Others 4 (7.1) 3 1
Unknown 4 (7.1) 1 3
Site of metastasis – no. (%)
Peritoneum 29 (52) 20 9 0.1413
Liver 11 (20) 7 4 0.5185
Ascites 21 (38) 13 8 0.4371
Peptide 0.1694
WT1 46 (82) 31 15
MUC1 39 (70) 27 12
CA125 16 (29) 7 9
Number of DC vaccine administration
Median (range) 7 (5–20) 7 (5–18) 7 (5–20) 0.6867
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32 (57%) had PD, and 8 (14%) were not evaluated. The
DCR and ORR were 29% and 3.6%, respectively (Table 2).
At the time of the final analysis, 35 patients (63%) had
died of cancer. Multivariate analysis revealed that an albu-
min level of ≥4.0 g/dL and a lactate dehydrogenase (LDH)Figure 1 Frequencies of CD4+ T cells, CD8+ T cells, and natural killer
immunotherapy targeting synthesized peptides for recurrent ovarian
cells (n = 31), and (C) natural killer cells (n = 31) are expressed as a percenlevel of <200 IU/L before vaccination were significantly as-
sociated with the MST from the first vaccination (Table 3).
The albumin level before vaccination was a significant fac-
tor for MST prolongation, as determined by the log-rank
test (P = 0.017; HR = 0.46; 95% CI, 0.18–0.85) and multi-
variate analysis. The MST from the first vaccination incells in patients before and after dendritic cell-based
cancer. (A) Data on frequencies of CD4+ T cells (n = 31), (B) CD8+ T
tage of peripheral blood mononuclear cells.
Figure 2 Frequency of Wilms tumor (WT) 1-specific cytotoxic
T lymphocytes (CTLs) in patients before and after therapy.
WT1-specific CTLs were detected using WT1 tetramers in 17 patients.
Data are expressed as a percentage of peripheral blood
mononuclear cells.
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19.9 and 11.6 months, respectively (Figure 3, Right). The
DCR and ORR were 36% and 5.5%, respectively, in the 36
(64%) patients with albumin levels of ≥4.0 g/dL. In con-
trast, these rates were 15% and 0%, respectively, in patients
with albumin levels of <4.0 g/dL (Table 2).
We used an NLR cutoff of 4 to evaluate the MST from
the first DC vaccine and found that the NLR was signifi-
cantly correlated with the MST by using the log-rank
test (P = 0.02; HR = 2.16; 95% CI, 1.15–5.97). The MST
of patients with an NLR of <4 was significantly longer
than that of patients with an NLR of ≥4 (19.9 vs.
9.5 months, Additional file 2). The DCR was 35% in pa-
tients with an NLR of <4 compared to 13% in those with
an NLR of ≥4 (Additional file 1: Table S1). Neither theFigure 3 Kaplan-Meier survival curves for the patients receiving dend
(dotted line) and from the first vaccination (solid line). (Right) Comparison
[solid line] and <4.0 g/dL [dotted line]).use of OK-432 nor the amount of OK-432 administered
was significantly associated with survival, indicating
that OK-432 itself did not affect the survival of patients
with ROC (log-rank test, P = 0.854, 14.5 vs. 19.9 months;
Wilcoxon, P = 0.498).
Discussion
Although some clinical trials of DC immunotherapy for
OC have been conducted, most of these were designed
with small sample sizes (approximately 11–22 patients)
and included patients with different stages of OC [8-10].
Differences in biological behavior and individual disease
burden were some of the issues encountered when com-
paring the efficacy of DC-based immunotherapy in het-
erogeneous patient populations, including patients with
recurrent, unresectable, and metastatic disease. The
present study was therefore designed to include only
ROC patients who had received prior chemotherapy
(Additional file 1: Table S2) in order to accurately as-
sess the therapeutic effects and evaluate alternative
approaches. Despite its retrospective design and small
sample size, the present study yielded 3 major findings
in ROC patients receiving the DC vaccine. First, DC-
based immunotherapy was well tolerated in all patients,
with no serious complications observed. Second, DC
administration may be adequate for generating immune
responses. Finally, according to multivariate analysis,
albumin levels of ≥4.0 g/dL and LDH levels of <200 IU/L
before vaccination were significant independent factors for
an improved MST.
In this study, the frequency of WT1-specific CTLs in-
creased in 12 (70.6%) of the 17 patients who were exam-
ined using the WT1-specific CTL tetramer assay. We
found that an increase in the frequency of WT1-specific
CTLs was not significantly associated with MST. In
addition, an increase in the frequency of WT1-specific
CTLs did not affect CD8+ T cells. Thus, an increase inritic cells-based vaccination. (Left) Survival curve from diagnosis
of the overall survival rates according to albumin levels (≥4.0 g/dL
Table 2 Clinical response to the DC vaccine
3 months 6 months
Clinical response All patients Alb ≥ 4.0 Alb < 4.0 All patients Alb ≥ 4.0 Alb < 4.0
N % N % N % N % N % N %
CR 0 0 0 0 0 0 0 0 0 0 0 0
PR 2 3.6 2 5.5 0 0 1 1.8 1 2.8 0 0
SD 14 25 11 30.6 3 15 7 12.5 5 13.9 2 10
PD 32 57.1 19 52.8 13 65 42 75 27 75 15 75
NE 8 14.3 4 11.1 4 20 6 10.7 3 8.3 3 15
Total 56 100 36 100 20 100 56 100 36 100 20 100
ORR* 2 3.6 2 5.5 0 0 1 1.8 1 2.8 0 0
DCR** 16 28.6 13 36.1 3 15 8 14.3 6 16.7 2 10
*Objective response rate (ORR), considers CR and PR.
**Disease control rate (DCR), considers CR, PR, and SD.
Table 3 Multivariate analysis of prognostic factors in ovarian cancer (n = 56)
Variable Log-rank Wilcoxon Cox’s hazard regression
Hazard ratio 95% CI P value
Hemoglobin (g/dL) ≥11 0.131 0.165 1 0.524-5.356 0.385
<11 1.675
Albumin (g/dL) ≥4.0 0.017 0.022 1 1.055-11.34 0.04
<4.0 3.459
LDH (IU/L) ≥200 0.107 0.131 1 0.077-0.975 0.046
<200 0.274
CRP (mg/dL) <0.5 0.009 0.01 1 0.757-13.47 0.114
≥0.5 3.192
Lymphocytes (/μL) ≥1,200 0.688 0.499 1 0.66-7.527 0.197
<1,200 2.229
Neutrophil (/μL) <4,000 0.766 0.853 1 0.291-4.046 0.903
≥4,000 1.085
Peritoneal metastasis Yes 0.273 0.483 1 0.137-1.038 0.059
No 0.378
Liver metastasis Yes 0.795 0.603 1 0.236-5.759 0.851
No 1.165
Ascites Yes 0.388 0.277 1 0.593-4.84 0.325
No 1.694
Fever after DC vaccine (°C) <38 0.657 0.72 1 0.235-3.549 0.896
≥38 0.913
Erythema (mm) ≥30 0.083 0.014 1 0.647-7.73 0.203
<30 2.236
WT1 peptide Yes 0.959 0.608 1 0.388-13.65 0.359
No 2.3
MUC1 peptide Yes 0.479 0.59 1 0.324-2.752 0.917
No 0.945
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to the MST. Similarly, although vaccine therapies devel-
oped to date have demonstrated immunological responses,
only minor clinical benefits have been observed [8,9,21].
ROC patients with initially platinum-sensitive disease
usually receive platinum-based regimens, even as second-
line chemotherapy. Their response rates range from 31%
to 66%, with a MST of 17–29 months [22,23]. In contrast,
the MST of platinum-resistant patients is only 10.6 months
[5]. In this study, the MST from diagnosis was 30.4 and
that from the first vaccination was 14.5 months. DC-based
immunotherapy was elected by the patients themselves
without our recommendations, leading to inconsistencies
in the date of DC-based immunotherapy initiation. There-
fore, although our results suggest that DC immunother-
apy might prolong survival time, we could not adequately
address the differences in survival benefits between our
study and previous ones because of the differences in
starting points for survival time calculation, patient popu-
lation, anticancer drugs, and therapy administration
schedules. A future prospective study with a larger sample
size is thus needed to confirm and validate our findings.
The clinical design of such a study should include 4 inde-
pendent prospective trials to compare chemotherapy
platinum-sensitive +/−DC-immunotherapy and platinum-
resistant +/−DC-immunotherapy in a controlled ROC pa-
tient population. Since DC-based immunotherapy has
been reported to show late efficacy [24], the appropriate
endpoint should be overall survival, regardless of the study
sample size.
The multivariate Cox proportional hazard analysis
identified albumin and LDH levels as significant inde-
pendent factors. Albumin levels are associated with
cachexia and ascites, leading to malnutrition in ROC pa-
tients. The nutritional status of a cancer patient, which
can be assessed by the serum albumin level, is known to
be associated with survival. Asher et al. [25] clearly dem-
onstrated that a low serum albumin level was associated
with poor survival and that the albumin level could be
an independent prognostic predictor of survival in OC
patients. In our previous study, low albumin levels were
responsible for poor prognosis in patients receiving DC
immunotherapy for biliary tract cancers [19], and the
same phenomenon was observed in this study on ROC
patients. In both studies, an albumin level of ≥4 g/dL
seemed to indicate suitability for DC immunotherapy,
and the nutritional status was found to be a promising
factor for promoting therapeutic effects.
LDH is a major enzyme in glycolysis that reversibly
catalyzes the conversion of pyruvate to lactic acid. Boran
et al. [26] showed that high serum LDH levels are linked
to a poor prognosis in patients with OC. There could be
several reasons for the ominous prognostic significance
of serum LDH in malignancies. For example, an acidicextracellular pH has been shown to activate gelatinase
activity and cathepsin D production, which helps in-
crease the invasiveness of cancer cells [27,28]. Addition-
ally, the lactate-mediated activation of macrophage-
associated angiogenesis might also facilitate metastasis
[29]. Finally, a low pH protects the mitochondria from
oxidative stress and could account for the increased re-
sistance of cancer cells to hypoxia-induced apoptosis
[30]. Further investigation is required to determine
whether the abovementioned or any additional mecha-
nisms underlie the strong and independent association
of LDH with the prognosis of ROC patients.
Inflammation plays a critical role in the pathogenesis
and progression of cancer. Recently, the derived NLR has
been shown to influence the clinical outcomes of various
cancer types, including ROC [20]. The number of neutro-
phils might reflect the levels of circulating angiogenesis-
regulating chemokines, growth factors, and proteases,
which are major contributors to tumor-related angiogen-
esis [31]. In addition, lymphocytes are involved in the pro-
duction of cytokines that inhibit the proliferation and
metastasis of tumor cells [32]. Therefore, the NLR could
act as a marker of the balance between the host inflamma-
tory and immune responses. In our study, patients with a
high NLR had a poor prognosis, suggesting that the NLR
might be another predictor of the MST in ROC patients.
A number of cancer-associated gene products evoke
immune recognition, but host reactions rarely impede
disease progression. A strong therapeutic effect has not
been confirmed in ROC patients. The weak immunogen-
icity of nascent tumors contributes to such a failure by
the host defense. Our next option to treat ROC patients
with DC immunotherapy is the concomitant use of ei-
ther antagonists of immune-repressor molecules or ago-
nists of immune-activating receptors such as checkpoint
blockade receptors comprising cytotoxic T-lymphocyte
associated antigen 4 (CTLA-4) (anti-CTLA-4 antibody,
ipilimumab; Bristol-Myers-Squibb, NY, USA) and pro-
grammed death-1 (PD-1) (anti-PD-L1 monoclonal anti-
body therapy, BMS-936559). These drugs serve to
accelerate antitumor immune responses and improve the
therapeutic effect potential in OC [33,34]. The combin-
ation of immunomodulatory properties with DC-based
immunotherapy targeting synthesized peptides might
help prolong the survival of ROC patients.Additional files
Additional file 1: Table S1. Clinical response to the DC vaccine according
to neutrophil-to-lymphocyte ratio. Table S2. Patient demographics, treatment
characteristics, and immunological responses.
Additional file 2: Comparison of the overall survival rates according
to the neutrophil-to-lymphocyte ratio (<4 [solid line] and ≥4
[dotted line]).
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